1. Lennon, VA, Wingerchuk, DM, Kryzer, TJ, et al A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106–2112. DOI: 10.1016/S0140-6736(04)17551.
Google Scholar | Crossref | Medline | ISI2. Wingerchuk, DM, Lennon, VA, Lucchinetti, CF, et al The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815. DOI: 10.1016/S1474-4422(07)70216.
Google Scholar | Crossref | Medline | ISI3. Misu, T, Takano, R, Fujihara, K, et al Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009; 80: 575–577. DOI: 10.1136/jnnp.2008.150698.
Google Scholar | Crossref | Medline | ISI4. Takano, R, Misu, T, Takahashi, T, et al Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75: 208–216. DOI: 10.1212/WNL.0b013e3181e2414b.
Google Scholar | Crossref | Medline | ISI5. Khalil, M, Teunissen, CE, Otto, M, et al Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14: 577–589. DOI: 10.1038/s41582-018-0058-z.
Google Scholar | Crossref | Medline6. Disanto, G, Barro, C, Benkert, P, et al Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–870. DOI: 10.1002/ana.24954.
Google Scholar | Crossref | Medline | ISI7. Mattsson, N, Cullen, NC, Andreasson, U, et al Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019; 76: 791–799. DOI: 10.1001/jamaneurol.2019.0765.
Google Scholar | Crossref | Medline8. Backstrom, D, Linder, J, Jakobson Mo, S, et al NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 2020; 95: e827–e838. DOI: 10.1212/WNL.0000000000010084.
Google Scholar | Crossref | Medline9. Watanabe, M, Nakamura, Y, Michalak, Z, et al Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 2019; 93: e1299–e1311. DOI: 10.1212/WNL.0000000000008160.
Google Scholar | Crossref10. Yang, CS, Yang, L, Li, T, et al Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013; 81: 710–713. DOI: 10.1212/WNL.0b013e3182a1aac7.
Google Scholar | Crossref | Medline | ISI11. Li, H, Huang, Z, Jia, D, et al Low-dose rituximab treatment for new-onset generalized myasthenia gravis. J Neuroimmunol 2021; 354: 577528. DOI: 10.1016/j.jneuroim.2021.577528.
Google Scholar | Crossref | Medline12. Wingerchuk, DM, Banwell, B, Bennett, JL, et al International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189. DOI: 10.1212/WNL.0000000000001729.
Google Scholar | Crossref | Medline | ISI13. Chen, J, Yang, X, Zhang, Y, et al Reference values for plasma neurofilament light chain (NfL) in healthy Chinese. Clin Chem Lab Med. Epub ahead of print 19 October 2020. DOI: 10.1515/cclm-2020-1030.
Google Scholar | Crossref14. Zhang, C, Zhang, M, Qiu, W, et al Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020; 19: 391–401. DOI: 10.1016/S1474-4422(20)30070-3.
Google Scholar | Crossref | Medline15. Kuhle, J, Kropshofer, H, Haering, DA, et al Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92: e1007–e1015. DOI: 10.1212/WNL.0000000000007032.
Google Scholar | Crossref | Medline16. Sejbaek, T, Nielsen, HH, Penner, N, et al Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry 2019; 90: 1324–1330. DOI: 10.1136/jnnp-2019-321321.
Google Scholar | Crossref | Medline17. Piehl, F, Kockum, I, Khademi, M, et al Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler 2018; 24: 1046–1054. DOI: 10.1177/1352458517715132.
Google Scholar | SAGE Journals | ISI18. de Flon, P, Laurell, K, Sundstrom, P, et al Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol Scand 2019; 139: 462–468. DOI: 10.1111/ane.13078.
Google Scholar | Crossref | Medline19. Akgun, K, Kretschmann, N, Haase, R, et al Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol Neuroinflamm 2019; 6: e555. DOI: 10.1212/NXI.0000000000000555.
Google Scholar | Crossref | Medline20. Canto, E, Barro, C, Zhao, C, et al Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol 2019; 76: 1359–1366. DOI: 10.1001/jamaneurol.2019.2137.
Google Scholar | Crossref | Medline21. Delcoigne, B, Manouchehrinia, A, Barro, C, et al Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 2020; 94: e1201–e1212. DOI: 10.1212/WNL.0000000000009097.
Google Scholar | Crossref | Medline22. Hauser, SL, Bar-Or, A, Cohen, JA, et al Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020; 383: 546–557. DOI: 10.1056/NEJMoa1917246.
Google Scholar | Crossref | Medline23. Kapoor, R, Smith, KE, Allegretta, M, et al Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology 2020; 95: 436–444. DOI: 10.1212/WNL.0000000000010346.
Google Scholar | Crossref | Medline24. Chang, X, Huang, W, Wang, L, et al Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front Immunol 2021; 12: 647618. DOI: 10.3389/fimmu.2021.647618.
Google Scholar | Crossref | Medline25. Hyun, JW, Kim, Y, Kim, SY, et al Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein. Neurol Neuroimmunol Neuroinflamm 2021; 8: e965. DOI: 10.1212/NXI.0000000000000965.
Google Scholar | Crossref26. Misu, T, Fujihara, K, Kakita, A, et al Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130: 1224–1234. DOI: 10.1093/brain/awm047.
Google Scholar | Crossref | Medline | ISI27. Petzold, A, Marignier, R, Verbeek, MM, et al Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry 2011; 82: 467–469. DOI: 10.1136/jnnp.2009.196550.
Google Scholar | Crossref | Medline28. Storoni, M, Petzold, A, Plant, GT. The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS ONE 2011; 6: e23489. DOI: 10.1371/journal.pone.0023489.
Google Scholar | Crossref | Medline29. Lee, EJ, Lim, YM, Kim, S, et al Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann Clin Transl Neurol 2020; 7: 992–1001. DOI: 10.1002/acn3.51070.
Google Scholar | Crossref | Medline30. Kim, H, Lee, EJ, Kim, S, et al Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 2020; 7: e708. DOI: 10.1212/NXI.0000000000000708.
Google Scholar | Crossref31. Aktas, O, Smith, MA, Rees, WA, et al Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol 2021; 89: 895–910. DOI: 10.1002/ana.26067.
Google Scholar | Crossref | Medline32. Ventura, RE, Kister, I, Chung, S, et al Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm 2016; 3: e224. DOI: 10.1212/NXI.0000000000000224.
Google Scholar | Crossref | Medline33. Jeong, IH, Choi, JY, Kim, SH, et al Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder. Eur J Neurol 2017; 24: 652–658. DOI: 10.1111/ene.13266.
Google Scholar | Crossref | Medline34. Ringelstein, M, Harmel, J, Zimmermann, H, et al Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 2020; 94: e407–e418. DOI: 10.1212/WNL.0000000000008684.
Google Scholar | Crossref | Medline35. Hogel, H, Rissanen, E, Barro, C, et al Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler 2020; 26: 210–219. DOI: 10.1177/1352458518819380.
Google Scholar | SAGE Journals | ISI36. Huss, A, Otto, M, Senel, M, et al A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course. Front Neurol 2020; 11: 608. DOI: 10.3389/fneur.2020.00608.
Google Scholar | Crossref | Medline